AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05478499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05478499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05945147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study NCT05945147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study NCT05945147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study NCT05945147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Study NCT04289571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VR Mobility Tool
Description: Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
Study NCT05025241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Study NCT05410665 — intervention group
Intervention type: PROCEDURE
Intervention: Standard treatments for sepsis
Description: Standard treatments for others
Study NCT05976867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers (PAT) as usual
Description: Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
Study NCT05976867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) + Smart Parents
Description: Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session.
Study NCT05293743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot abduction bracing for clubfoot with novel Dynamic Bar
Description: After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.
Study NCT05293743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot abduction bracing for clubfoot with Standard Bar
Description: After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
Study NCT04466956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality headset worn with short relaxing video played during MVA procedure
Study NCT04711824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
Study NCT04711824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: SRS 1-5 fractions will be given per institutional standards
Study NCT04711824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
Study NCT04711824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physicians Choice systemic chemotherapy
Description: Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
Study NCT06083883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)
Study NCT06083883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 TCR/IL-15 NK
Description: Given by IV (vein)
Study NCT06083883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT05192954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSureTM vessel sealing device
Description: Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
Study NCT06083220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Start - School Readiness Program
Description: Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
Study NCT05088980 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VOLBELLA with Lidocaine
Description: Facial Injection
Study NCT05088980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLBELLA with Lidocaine
Description: Facial Injection
Study NCT05394428 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01451450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 liquid for subcutaneous injection.
Study NCT04624750 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine
Description: Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study.
Study NCT05633095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuclare
Description: It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
Study NCT05949931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent penpulimab and AVD
Description: Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
Study NCT05949931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential penpulimab and AVD
Description: Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
Study NCT01451450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid for subcutaneous injection.
Study NCT05214599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Gel
Description: Twice daily regimen
Study NCT06290362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Theory-based group consultation
Description: Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events.
Study NCT05965622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)
Description: Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU).
Study NCT05965622 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
Study NCT06568978 — intervention group
Intervention type: OTHER
Intervention: Assessments of respiratory parameters
Description: respiratory muscle strength, respiratory function test
Study NCT06274853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: Oral GS-441524 capsules
Study NCT06274853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT06301737 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive rehabilitation
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.
Study NCT06301737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.
Study NCT06301737 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06301737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06015724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: anti-CD38 monoclonal antibody (mAb)
Study NCT06015724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS vaccine
Description: Stimulon QS-21 and Targovax TG01
Study NCT06015724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
Study NCT05754905 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance examination
Description: the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
Study NCT06572436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia information training
Description: The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
Study NCT05739058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Violet-Blue Light Treatment / FlashHeal Device
Description: FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz.
Study NCT06447038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio
Description: Albumin creatinine ratio, this test is routinely performed in urine.
Study NCT06662604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells concentrate , platelet rich fibrin , bone graft
Description: All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
Study NCT06662604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin and bone graft
Description: All participants will treated with platelet rich fibrin PRF , bone graft.
Study NCT06670404 — intervention group
Intervention type: DEVICE
Intervention: Vertebroplasty
Description: Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
Study NCT06669013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Chemotherapy + Immunotherapy (dinutuximab beta)
Study NCT04872127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal embolism protection device
Description: a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
Study NCT04872127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distal embolism protection device
Description: a distal SpiderFX will be used as the embolism protection device during CAS
Study NCT04349826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 20 mg/kg/day for 7 days
Study NCT04349826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 20 mg/kg/day for 7 days
Study NCT04349826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime
Description: cefixime 20-30 mg/kg/day for 7 days
Study NCT04349826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cefixime-matched placebo for 7 days
Study NCT05892965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study NCT05779488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: maca
Description: 2.25 g of Maca extract, twice per day for 12 weeks
Study NCT05779488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.25 g of starch, twice per day for 12 weeks
Study NCT05344560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore
Description: TEST Lens
Study NCT05344560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: CONTROL Lens
Study NCT06578000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).
Study NCT06578000 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy (Splint + Stretch + strength) twice a week for six weeks
Study NCT06578000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy (Splint + Stretch + strength) twice a week for six weeks
Study NCT06119386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexon-Eye
Description: In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
Study NCT05507268 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04973176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bougie
Description: Standard Bougie for endotracheal intubation
Study NCT04973176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi-tip Bougie (P3 Medical Bristol,UK)
Description: Flexi-tip Bougie for endotracheal intubation